Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether PXT3003 is effective and safe in the
treatment of Charcot-Marie-Tooth disease - Type 1A. This double-blind study will assess in
parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients treated for 15
months.